NEWS Office letting Hammersmith, Catalyst Capital signs up new tenant to Kings House

Kings House Catlyst Capital new tantt

Office letting Hammersmith
Catalyst Capital has completed the first letting at Kings House, a 60,000 sq ft office building in Hammersmith.

Kings House Reception photo Office letting Hammersmith
Kings House reception

The European real estate investment and asset management firm bought the seven-storey office building for £50m on behalf of a private investor at the end of 2019.

Global pharmaceutical company Alvogen has taken 5,500 sq ft on a five year lease, leaving just 6,500 sq ft on the first floor available before full occupancy is achieved at Kings House.

Alvogen Logo Office letting Hammersmith

This will be Alvogen’s first UK office base as it continues to grow. Alvogen joins a range of occupiers including HyperOptic, Work.Life, 4C Associates, Zaizi and SailGB.

Catalyst Capital is advised by Frost Meadowcroft and Lambert Smith Hampton.

Justin Clack, director at Frost Meadowcroft said: “We think that the Covid-19 crisis will mean that the tenants are more likely to lease the ‘best in class’ offices available in individual submarkets, such as Kings House in Hammersmith”.

Sarah Cooper, portfolio manager for Catalyst Capital, added:“We are delighted to welcome Alvogen to Kings House. Its offices have been fitted to a high specification, which in turn reflects the quality of the building in a prime location within Hammersmith”.

ABOUT THE LANDLORD

Catalyst Capital LLP was created in 2001 through a management buyout of the European arm of Greenwich Group International. The senior partners of Catalyst have been working together since 1994 and have been managing investments since 1996, and have an average of 30 years’ experience in the real estate industry. From inception, Catalyst has adopted an activist approach to investment and its management.

ABOUT THE TENANT

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. With commercial footprint in over 20 markets, Alvogen’s key regions include the U.S. and APAC regions.